2639 Results

People

  1. Zelenetz
    Zelenetz
  2. Horwitz
    Horwitz
  3. Palomba
    Palomba
  4. Noy
    Noy
  5. Moskowitz
    Moskowitz
  6. Younes
    Younes
  7. Matasar
    Matasar
  8. Moskowitz
    Moskowitz
  9. Yahalom
    Yahalom
  10. Portlock
    Portlock

Groups

  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)
  7. Executive Committee, Center for Hematologic Malignancies (389)
  8. Epidemiology and Biostatistics (363)
  9. GSK Faculty (356)
  10. Department of Pathology and Laboratory Medicine (300)
  1. "Lymphoma"
Formats
  1. Meeting Abstract (1340)
  2. Journal Article (1048)
  3. Book Section (63)
  4. Review (63)
  5. Editorial (37)
  6. Research Letter (35)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)

More Groups

People
  1. Andrew Zelenetz (767)
  2. Steven Horwitz (645)
  3. Maria Palomba (415)
  4. David Straus (356)
  5. Ariela Noy (351)
  6. Alison Moskowitz (339)

More People

Years
  1. 2025 (28)
  2. 2024 (100)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (833)
  2. Journal of Clinical Oncology (274)
  3. Hematological Oncology (110)
  4. Leukemia and Lymphoma (81)
  5. British Journal of Haematology (79)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (898)
  2. American Society of Clinical Oncology (290)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (173)
  5. John Wiley & Sons (95)
  6. Nature Publishing Group (92)

More Publishers

Results (2639)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes of pharmacokinetically (PK) directed busulfan in combination with thiotepa & cyclophosphamide (TBC) conditioning with HDT-ASCT in patients with primary & secondary CNS lymphoma
    Meeting Abstract

    Bhatt, V.; Scordo, M.; Hsu, M.; Omuro, A. M.; DeAngelis, L.; Lin, A.; Matasar, M. J.; Dahi, P. B.; Moskowitz, C. H.; Giralt, S. A.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Defining the incidence and clinical impact of genomic alterations across different histologic types of lymphoma using a clinically validated comprehensive targeted sequencing assay
    Meeting Abstract

    Batlevi, C.; Rapaport, F.; Intlekofer, A. M.; Reiner, A.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, L.; Moskowitz, A. J.; Gerecitano, J. F.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Distinctive genomic alterations in testicular diffuse large B cell lymphoma
    Meeting Abstract

    Batlevi, C.; Rapaport, F.; Wang, L.; Intlekofer, A. M.; Copeland, A. R.; Jungbluth, A. A.; Reiner, A.; Pichardo, J. D.; Gallagher, M.; Bouvier, N.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • An open-label phase II study of buparlisib (BKM120) in patients with relapsed and refractory diffuse large B-Cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and follicular lymphoma (FL)
    Meeting Abstract

    Younes, A.; Salles, G.; Martinelli, G.; Bociek, R. G.; Barrigon, D. C.; Barca, E. G.; Turgut, M.; Gerecitano, J. F.; Herbst, F.; Williams, L.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Phase 1 trial testing single agent CUDC-907, a novel, oral dual inhibitor of histone deacetylase (HDAC) and PI3K: Initial assessment of patients with relapsed or refractory (RR) diffuse large B-Cell lymphoma (DLBCL), including double expressor (DE) lymphoma
    Meeting Abstract

    Younes, A.; Berdeja, J. G.; Patel, M. R.; Kelly, K. R.; Flinn, I. W.; Gerecitano, J. F.; Neelapu, S. S.; Copeland, A. R.; Akins, A.; Clancy, M.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory chronic lymphocytic leukemia: Results of a phase 3 randomized double-blind placebo-controlled study
    Meeting Abstract

    Zelenetz, A. D.; Robak, T.; Coiffier, B.; Delgado, J.; Marlton, P.; Adewoye, A. H.; Kim, Y.; Dreiling, L. K.; Hillmen, P.
    Blood (2015)

    Fulltext@MSK | Save
  • The clonal architecture of CXCR4 mutations in Waldenstrom's Macroglobulinemia shows highly variable subclonal distribution, and multiple mutations within individual patients indicative of targeted genomic instability
    Meeting Abstract

    Xu, L.; Hunter, Z.; Tsakmaklis, N.; Cao, Y.; Yang, G.; Chen, J.; Liu, X.; Kanan, S.; Castillo, J. J.; Tai, Y. T.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Initial results of US intergroup trial of response-adapted chemotherapy or chemotherapy/radiation therapy based on PET for non-bulky stage I and II Hodgkin lymphoma (HL) (CALGB/Alliance 50604)
    Meeting Abstract

    Straus, D. J.; Pitcher, B.; Kostakoglu, L.; Grecula, J. C.; Hsi, E. D.; Schoder, H.; Jung, S. H.; Popplewell, L. L.; Chang, J. E.; Moskowitz, C. H.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Preliminary results from a phase 1/2, open-label, dose-escalation clinical trial of IMO-8400 in patients with relapsed or refractory Waldenstrom's macroglobulinemia
    Meeting Abstract

    Thomas, S. K.; Harb, W. A.; Beck, J. T.; Nashat, G.; Palomba, M. L.; Ansell, S. M.; Eradat, H.; Libby, E. N.; Advani, R. H.; Hajdenberg, J.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • A clinicogenetic risk model (m7-FLIPI) prospectively identifies one-half of patients with early disease progression of follicular lymphoma after first-line immunochemotherapy
    Meeting Abstract

    Vindi, J.; Kridel, R.; Staiger, A. M.; Szczepanowski, M.; Horn, H.; Dreyling, M. H.; Rosenwald, A.; Ott, G.; Klapper, W.; Zelenetz, A. D.; more...
    Blood (2015)

    Fulltext@MSK | Save